About Immunoglobulin superfamily member 11
Immunoglobulin superfamily member 11 (IGSF11) is a protein
from Homo sapiens identified by UniProt accession
Q5DX21, 431 residues long.
MolForge cross-references it against 0 known binders and
130 disease associations.
Target properties
| Protein name | Immunoglobulin superfamily member 11 |
| UniProt accession | Q5DX21 |
| Gene | IGSF11 |
| Organism | Homo sapiens |
| Length | 431 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (130)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.41
- Abnormality of refraction · score 0.32
- intelligence · score 0.31
- schizophrenia · score 0.31
- age at first sexual intercourse measurement · score 0.25
- hip bone mineral density · score 0.25
- attention deficit hyperactivity disorder · score 0.25
- antisocial behaviour measurement · score 0.24
- substance abuse · score 0.24
- cystatin C measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5DX21-F1 | alphafold | PREDICTED | 73.68 | — |
Amino-acid sequence (431 residues)
MTSQRSPLAP LLLLSLHGVA ASLEVSESPG SIQVARGQPA VLPCTFTTSA ALINLNVIWM VTPLSNANQP EQVILYQGGQ MFDGAPRFHG RVGFTGTMPA TNVSIFINNT QLSDTGTYQC LVNNLPDIGG RNIGVTGLTV LVPPSAPHCQ IQGSQDIGSD VILLCSSEEG IPRPTYLWEK LDNTLKLPPT ATQDQVQGTV TIRNISALSS GLYQCVASNA IGTSTCLLDL QVISPQPRNI GLIAGAIGTG AVIIIFCIAL ILGAFFYWRS KNKEEEEEEI PNEIREDDLP PKCSSAKAFH TEISSSDNNT LTSSNAYNSR YWSNNPKVHR NTESVSHFSD LGQSFSFHSG NANIPSIYAN GTHLVPGQHK TLVVTANRGS SPQVMSRSNG SVSRKPRPPH THSYTISHAT LERIGAVPVM VPAQSRAGSL V
Explore Immunoglobulin superfamily member 11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets